Ascelia Pharma (Q3 review): Partnering in focus ahead - Redeye
Redeye returns with an update following Ascelia Pharma's Q3 update, which contained no surprises. We make some near term changes to our estimates but largely reiterate our view.
ANNONS
Redeye returns with an update following Ascelia Pharma's Q3 update, which contained no surprises. We make some near term changes to our estimates but largely reiterate our view.
